Maxime Dely on a Hopeful Horizon: Promising Advances in Extending Platelet Power
Maxime Dely, Sales and Application Specialist in Therapeutic Apheresis and Cell Therapy, shared a post on LinkedIn:
“Platelets don’t sleep: The race to preserve their power longer
This is one of the most strategic questions in transfusion medicine today, as demand rises and logistical constraints tighten.
Platelets are unique cells: living, sensitive, and highly reactive. The moment they leave the human body, they begin a slow deterioration known as the “storage lesion”.
This process alters their metabolism, shape, and aggregation capacity — ultimately impacting their clinical effectiveness.
For a long time, this degradation was considered inevitable. But recent advances are changing the landscape.

Current research highlights several promising pathways:
• Platelet additive solutions (PAS) help reduce spontaneous activation and improve metabolic stability.
• Cold storage, once abandoned, is making a strong comeback thanks to its preservation of hemostatic function.
• Enhanced bag materials, pH control, and optimized agitation help limit the metabolic drift seen over time.
• Monitoring activation markers opens the door to finer, potentially dynamic quality control.
For hospital teams, the impact could be significant: less waste, more flexibility, and better matching between product and patient.
For patients, it means more effective and potentially safer transfusions.
When we look at a platelet concentrate today, we no longer just see a blood product — we see the result of years of research and the early signs of a new generation of transfusion solutions.
What if the next revolution simply came from a better way to preserve what saves lives every day?”
Advance your knowledge with Hemostasis Today.
-
Dec 6, 2025, 18:02ASH25 Day 1: Don’t Miss The Highlights
-
Dec 6, 2025, 15:44Atul Gupta on Where The Healthcare Innovation is Headed
-
Dec 6, 2025, 15:22Nathan White on How Inflammation Contributes to Coagulopathy After Trauma
-
Dec 6, 2025, 15:02Anas Younes on AstraZeneca’s Aims in Blood Cancer to Be Presented at ASH25
-
Dec 6, 2025, 14:08David Alderman: ASH25 is Live
-
Dec 6, 2025, 13:53Isabelle Mahé Presents The Proposals from INNOVTE CAT Working Group
-
Dec 6, 2025, 11:50Steve Tuplin on Roche’s Mission at ASH25
-
Dec 6, 2025, 11:13Khaled Musallam on The Lancet Haematology Podcast: Your ASH25 Roadmap
-
Dec 5, 2025, 03:46Sreeni Sivan Pillai: Preventing Thrombophlebitis and Upper Limb DVT in PICC Lines
